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A covalent adduct of norchlorpromazine (CAPP) and calmodulin is a very potent antagonist of 
calmodulin activation of several enzymes. The phenothiazine-calmodulin complex (CAPP-calmodulin) 
acts as a pure antagonist with phosphodiesterase and myosin kinase or a partial agonist with the 
phosphoprotein phosphatase, calcineurin. Because of its potency and the selectivity inherent to its 
calmodulin moiety, CAPP-calmodulin should be a uniquely useful probe of calmodulin actions. 
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1. INTRODUCTION 
In the presence of Ca’+, phenothiazines bind to 
calmodulin and thereby prevent the activation of 
calmodulin-regulated enzymes (review [ 11). 
Because phenothiazines lack specificity [2-41, have 
a low affinity for calmodulin [l] and interact also 
with calmodulin target proteins [5-71, their 
usefulness as probes of calmodulin function is 
limited. Recently, we described the Ca’+- 
dependent formation of a covalent, one to one, 
complex of calmodulin with norchlorpromazine 
isothiocyanate (CAPP-NCS) [8]. This drug- 
calmodulin adduct (CAPP-calmodulin) lacks the 
ability to stimulate the calmodulin-dependent 
cyclic nucleotide phosphodiesterase, but can still 
interact with the enzyme and prevent the stimula- 
tion of the enzyme by calmodulin. Thus, CAPP- 
calmodulin contains a phosphodiesterase binding 
site. We demonstrate here that by covalently at- 
taching a phenothiazine to calmodulin, we have 
created a calmodulin antagonist which not only is 
specific for calmodulin-dependent reactions, but is 
50-300 times more potent than unconjugated 
phenothiazines as a calmodulin antagonist. 
2. MATERIALS AND METHODS 
Trifluoperazine (TFP) was a gift from Smith 
Kline and French Laboratories; all other reagents 
were as in [8,9]. Ram testis calmodulin [9], CAPP- 
calmodulin [8], calmodulin-stimulated cyclic 
nucleotide phosphodiesterase [lo] and calcineurin 
[l l] were prepared according to published 
methods. Dephosphorylated chicken gizzard 
smooth muscle myosin light chains [12], and 
myosin kinase [ 131 were gifts of Dr David R. 
Hathaway, Indiana University School of 
Medicine. 
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CAMP phosphodiesterase was assayed after a 40 
min incubation at 30°C as in [8]. The reaction was 
initiated by addition of enzyme 5 x 10-l’ M). 
Myosin kinase incubations [131 were at 37°C for 15 
min. The reaction mixture (0.06 ml) contained 20 
mM Tris-HCl (pH 7.5), 10 mM MgClz, 10m5 M 
myosin light chains, 0.4 mM Ca*+ or 2 mM EGTA, 
0.1 mM [y-32P]ATP (4.0 x 16 cpm/nmol) in the 
presence or absence of calmodulin (10-5-10-10 M). 
The reaction was initiated by the addition of en- 
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zyme (lo-” M) and was terminated by applying 
50-~1 aliquots to Whatman 3 MM filter discs which 
were immediately immersed in chilled 10% tri- 
chloroacetic acid containing 40 mM sodium 
pyrophosphate. The filter discs were washed 3 
times with trichloroacetic acid and once with 95% 
EtOH (15 min each time) and were counted in a 
Beckman LS 335 scintillation spectrometer after 
addition of 7.5 ml aquasol. Calcineurin was 
assayed using p-nitrophenylphosphate as substrate 
[9]. Calcineurin concentration was lo-* M. The 
reaction was initiated by the addition of substrate 
to a final concentration of 2.5 mM. The linear rate 
of appearance of p-nitrophenolate was monitored 
at 400 nm at 23°C over 15 min. Appropriate ali- 
quots of TFP (stock solution, 5.6 mM in HzO) or 
CAPP-calmodulin (stock solution, 2.3 x lo-’ M 
in 0.05 M NHdHCOj) were added as indicated. 
Serial dilutions of TFP were made in Hz0 and 
those of CAPP-calmodulin in 0.5 mg/ml bovine 
serum albumin. 
3. RESULTS 
In the experiments reported here, the activity of 
TFP is compared with that of CAPP-calmodulin. 
TFP rather than CAPP was used as the 
phenothiazine antagonist because TFP is more 
soluble than CAPP and has a Ki value similar to 
that of CAPP as an antagonist of calmodulin. 
CAPP-calmodulin and TFP inhibit the stimulation 
of phosphodiesterase by calmodulin (fig. 1). The 
inhibition is competitive in both cases. TFP inhibi- 
tion was completely overcome by increasing the 
concentration of calmodulin to lo-’ M. In the case 
of CAPP-calmodulin, complete reversal was 
observed only when the inhibitor was present at 
less than 10d6 M (not shown). CAPP-calmodulin 
was about 50 times more potent than TFP in an- 
tagonizing the calmodulin stimulation of the en- 
zyme. Assuming simple competitive inhibition, the 
following kinetic constants were obtained: K, for 
calmodulin, 3 f 0.5 x 10e9 M; Ki for CAPP- 
calmodulin, 3.0 f 1.0 x lo-* M; Ki for TFP, 1.5 
f 0.3 x 10m6 M (the Ki value for CAPP is 0.9 +- 
0.2 x 1O-6 M). 
Similar results were obtained with myosin kinase 
(fig.2). Again CAPP-calmodulin was more effec- 
tive (about 3OO-fold) than TFP in preventing ac- 
tivation by calmodulin, and the inhibition was 
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Fig. 1. Inhibition of the calmodulin stimulation of phos- 
phodiesterase by TFP and CAPP-calmodulin. CAMP 
phosphodiesterase was assayed as described in section 2. 
Activation of phosphodiesterase by calmodulin (0); in- 
hibition of calmodulin stimulation of phosphodiesterase 
by 10e5 M TFP (A), and 1O-6 M TFP (A) or 10m6 M 
CAPP-calmodulin (0). Each point is representative of 
triplicate determinations. 
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Fig.2. Inhibition of calmodulin stimulation of myosin 
kinase by TFP and CAPP-calmodulin. Myosin kinase 
was assayed as described in section 2. Activation by 
calmodulin (0); inhibition of calmodulin activation by 
10m5 M TFP (A), and 10m6 M TFP (A) or 10m6 M CAPP- 
calmodulin (0). 
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Fig.3. (A) Stim~ation of calcineurin phosphatase activity by calmodulin and CAPP-~almodulin. Calcineurin was 
assayed as described in section 2. (B) Inhibition of caimodulin stimulation of calcineurin by TFP and CAPP- 
calmodulin. The arrows indicate the concentration of caicineurin in the assay mixture. 
competitive. Based on the same assumption, a Ka 
value for calmodulin of 7 f 2 x lo-’ M, a Ki 
value for CAPP-calmodulin of 3.4 t 1.0 x 10M9 
M and a Ki value for TFP of 1 .O f 0.4 x 10v6 M 
were obtained. 
TFP and CAPP-caimodulin were also inhibitors 
of the calmodulin stimulation of calcineurin, a 
phosphoprotein phosphatase [14], but with more 
complex kinetics. Whereas CAPP-calmodulin does 
not activate phosphodiesterase or myosin kinase 
(fig. 1,2), it does activate calcineurin to 40-50% of 
the maximal level achieved by calmodulin (fig.3A). 
The activation is Ca2’-dependent. In contrast, 
TFP is unable to activate calcineurin in the 
presence or absence of Ca2+. Because CAPP- 
calmodulin activation of calcineurin is only par- 
tial, it becomes inhibitory at calmodulin concen- 
trations high enough to produce near maximal ac- 
tivation (fig.3B). As observed with phospho- 
diesterase and myosin kinase, the inhibition can be 
overcome by sufficiently high calmodulin concen- 
trations (fig.3B). The kinetic constants were not 
calculated here because the activation curves were 
determined at lo-* M calcineurin so that the con- 
centration of free calmodulin was far from the 
amount added. Under these conditions, the af- 
finities of CAPP-calmodulin and calmodulin for 
calcineurin were both 15 x 10e9 M. 
4. DISCUSSION 
The covalent linking of 1 mol of the anti- 
psychotic drug, norchlorpromazine, to 1 mol of 
calmodulin transforms this low affinity and non- 
specific inhibitor of calmodulin into a high affinity 
and specific calmodulin antagonist. Whereas TFP 
(or CAPP) inhibits c~modulin-regulated reactions 
with a Ki value near low6 M, CAPP-caImodulin in- 
hibits the same reactions with a Ki value 2-3 orders 
of magnitude lower (3 x lo-’ to 3 x low9 M). 
Thus, the one to one phenothiazine-calmodulin 
complex interacts with the 3 enzymes studied with 
an affinity only slightly lower than that of 
calmodulin. Phenothi~ines can therefore inhibit 
c~modulin actions in two ways. The first 
mechanism, as proposed by other investigators 
[ 1 S-171, involves the formation of a calmodulin- 
phenothiazine complex which cannot interact with 
the enzyme, thereby preventing enzyme activation. 
A second mechanism of inhibition, as shown here, 
271 
Volume 165, number 2 FEBS LETTERS January 1984 
is by forming a phenothiazine-calmodulin com- 
plex which will interact with the enzyme with a 
relatively high affinity via its calmodulin moiety 
but either does not activate the enzyme (as with 
phosphodiesterase and myosin kinase) or activates 
the enzyme only partially (as with calcineurin). 
Whether one or both types of mechanisms of in- 
hibition operate normally is not yet clear. It is 
clear, however, that CAPP-calmodulin is a much 
more specific probe of calmodulin function than 
are the phenothiazines themselves. 
REFERENCES 
111 
PI 
[31 
141 
t51 
Prozialeck, W.C. and Weiss, B. (1982) J. 
Pharmacol. Exp. Ther. 222, 509-516. 
Marshak, D.R., Watterson, D.M. and Van Eldik, 
L. J. (1981) Proc. Natl. Acad. Sci. USA 78, 
6793-6797. 
Moore, P.B. and Dedman, J.R. (1982) J. Biol. 
Chem. 257, 9663-9667. 
Mori, T., Takai, Y., Minakuchi, R., Yu, B. and 
Nishizuka, Y. (1980) J. Biol. Chem. 255, 
8378-8380. 
Gietzen, K., Sadorf, I. and Bader, H. (1982) 
Biochem. J. 207, 541-548. 
El 
[71 
PI 
191 
WI 
ill1 
WI 
[I31 
1141 
1151 
1161 
u71 
Adunyah, E.S., Niggli, V. and Carafoli, E. (1982) 
FEBS Lett. 143, 65-68. 
Klee, C.B., Newton, D.L. and Krinks, M. (1983) 
Proc. of the Fifth International Symposium on 
Affinity Chromatography and Biological 
Recognition, in press. 
Newton, D.L., Burke, T.R., jr., Rice, K.C. and 
Klee, C.B. (1983) Biochemistry, in press. 
Newton, D.L., Oldewurtel, M.D., Krinks, M.H., 
Shiloach, J. and Klee, C.B. (1983) submitted. 
Klee, C.B., Crouch, T.H. and Krinks, M.H. (1979) 
Biochemistry 18, 722-729. 
Klee, C.B., Krinks, M.H., Manalan, A.S., Cohen, 
P. and Stewart, A. A. (1983) Methods Enzymol. 
102, 227-244. 
Hathaway, D.R. and Haeberle, J.R. (1983) Anal. 
Biochem., in press. 
Adelstein, R.S. and Klee, C.B. (1981) J. Biol. 
Chem. 256, 7501-7509. 
Stewart, A.A., Ingrebritsen, T.S., Manalan, A., 
Klee, C.B. and Cohen, P. (1982) FEBS Lett. 137, 
80-84. 
LaPorte, D.C., Wierman, B.M. and Storm, D.R. 
(1980) Biochemistry 19, 3814-3819. 
Tanaka, T., Ohmura, T. and Hidaka, H. (1983) 
Pharmacology 26, 249-257. 
Abe, T. and Saisu, H. (1982) Biomedical Res. 3, 
207-212. 
272 
